Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Factors to Consider The Zacks Consensus Estimate for Iovance's total revenues is pegged at around $2.9 million, while the same for earnings stands at a loss of 45 cents per share. Both metrics indicate improvements over the year-ago quarter's levels. Iovance has two marketed products in its portfolio — Amtagvi (lifileucel) and Proleukin (aldesleukin). While the FDA recently approved Amtagvi under the accelerated pathway to treat advanced melanoma, Proleukin was added to the company's portfolio last year to treat two cancer indications — metastatic renal cell carcinoma (mRCC) and metastatic melanoma. Though Proleukin was Iovance's first marketed product, sales from the drug are yet to contribute to the top line. Given the accelerated approval for Amtagvi was received in the third week of February, we expect Amtagvi sales to be modest. Investors will likely be seeking an update from management on the current progress of the commercial launch for Amtagvi and sales guidance. Apar
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- The sun's out, so you need to think about prevention of this type of cancer [CNN]CNN
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi [Seeking Alpha]Seeking Alpha
IOVA
Earnings
- 5/9/24 - Beat
IOVA
Sec Filings
- 5/17/24 - Form DEFA14A
- 5/10/24 - Form S-8
- 5/9/24 - Form 10-Q
- IOVA's page on the SEC website